Table 1.
Clinical characteristics of subjects included in the study cohorts
| Characteristics | Late DKD | Early DKD | |||
|---|---|---|---|---|---|
| Joslin T1D Discovery Cohort (n=239)a | Joslin T2D Replication Cohort (n=136)a | Joslin T1D Validation Cohort (n=243)b | Pima T2D Validation Cohort (n=154)a | Pima T2D Cohort for Auxiliary Study (n=105)c | |
| At baseline | |||||
| Male/female, n | 117/122 | 89/47 | 133/110 | 43/111 | 29/76 |
| Age (yr), mean±SD | 44±10 | 60±6 | 39±9 | 46±10 | 45±10 |
| Duration of DM (yr), mean±SD | 30±9 | 16±9 | 26±9 | 16±7 | 15±6 |
| HbA1c (%), mean±SDd | 8.6±1.6 | 7.5±1.8 | 9.0±1.7 | 9.4±2.3 | 9.2±2.3 |
| SBP (mmHg), mean±SD | 136±20 | 139±19 | 131±19 | 125±14 | 122±13 |
| DBP (mmHg), mean±SD | 77±11 | 75±11 | 78±10 | 77±9 | 77±9 |
| ACR (mg/g), median (IQR) | 793 (274–1855) | 255 (57–1092) | 579 (212–1173) | 55 (13–357) | 40 (12–124) |
| GFR (ml/min), mean±SDe | 42±10 | 49±11 | 97±21 | 150±47 | 151±47 |
| During follow-up | |||||
| New cases of ESKD within 10 yr, n (%) | 127 (53) | 43 (32) | 50 (21) | 37 (24) | 15 (14) |
DM, diabetes mellitus; SBP, systolic BP; DBP, diastolic BP; IQR, interquartile range.
a
These study cohorts were used to study KRIS proteins, and their clinical characteristics were previously reported.12
b
This study cohort was used to study TNF-related proteins, and clinical characteristics were previously reported.13
c
This subgroup from the Pima T2D validation cohort had kidney biopsies and was used to study kidney structural lesions.